ISIN | LU2488093530 |
---|---|
Valorennummer | 119401713 |
Bloomberg Global ID | |
Fondsname | Kieger Impact Healthcare Fund Class B CHF Accumulating |
Fondsanbieter |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Telefon: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fondsanbieter | Kieger AG |
Vertreter in der Schweiz |
ACOLIN Fund Services AG Zürich Telefon: +41 44 396 96 96 |
Distributor(en) | |
Anlagekategorie | Aktienfonds |
EFC-Kategorie | |
Anteilskategorie | Accumulation |
Domizilland | Luxemburg |
Konditionen bei der Ausgabe | keine Ausgabekommission und/oder Gebühren zugunsten des Fonds (Ausgabe erfolgt zum Inventarwert) |
Konditionen bei der Rücknahme | Keine Rücknahmekommission und/oder Gebühren zugunsten des Fonds (Rücknahme erfolgt zum Inventarwert) |
Investment-Strategie *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
Besonderheiten |
Aktueller Preis * | 86.10 CHF | 31.10.2024 |
---|---|---|
Vorheriger Preis * | 87.54 CHF | 30.10.2024 |
52 Wochen Hoch * | 98.66 CHF | 15.05.2024 |
52 Wochen Tief * | 79.97 CHF | 09.11.2023 |
NAV * | 86.10 CHF | 31.10.2024 |
Ausgabepreis * | ||
Rücknahmepreis * | ||
Schlusskurs * | ||
Indikativer Minimalpreis | ||
Fondsvermögen *** | 69'981'458 | |
Anteilsklassevermögen *** | 8'610 | |
Trading Information SIX |
YTD-Performance | -5.75% |
29.12.2023 - 31.10.2024
29.12.2023 31.10.2024 |
---|---|---|
1 Monat | -3.01% |
30.09.2024 - 31.10.2024
30.09.2024 31.10.2024 |
3 Monate | -6.57% |
31.07.2024 - 31.10.2024
31.07.2024 31.10.2024 |
6 Monate | -7.84% |
30.04.2024 - 31.10.2024
30.04.2024 31.10.2024 |
1 Jahr | +4.85% |
31.10.2023 - 31.10.2024
31.10.2023 31.10.2024 |
2 Jahre | -13.90% |
20.03.2023 - 31.10.2024
20.03.2023 31.10.2024 |
3 Jahre | - | - |
5 Jahre | - | - |
Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
ResMed Inc | 4.00% | |
---|---|---|
Tandem Diabetes Care Inc | 3.74% | |
Hikma Pharmaceuticals PLC | 3.63% | |
Ambu AS Class B | 3.43% | |
Sandoz Group AG Registered Shares | 3.39% | |
Guardant Health Inc | 3.37% | |
Ionis Pharmaceuticals Inc | 3.34% | |
GSK PLC | 3.34% | |
Natera Inc | 3.32% | |
BioNTech SE ADR | 3.31% | |
Letzte Daten-Aktualisierung | 30.04.2024 |
TER *** | 1.22% |
---|---|
Datum TER *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.00% |
Ongoing Charges *** | |
SRRI ***
|
|
Datum SRRI *** | 30.09.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |